$GKOS

$163.05▲ +1.0% YTD

6 SEC 13D/G filings tracked · Last updated Oct 9, 2026

Filing History

CP $163.05▲ +1.0%Oct 9, 2026 · ThinkSabio Blog

$GKOS - Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination w…

News

GKOS ▼ -0.2% - Glaukos Corporation

CP $171.93▲ -0.2%Oct 8, 2026 · ThinkSabio Blog

$GKOS - Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Bi…

News

GKOS ▲ +8.5% - Glaukos Corporation

CP $175.37▲ +8.5%Oct 7, 2026 · ThinkSabio Blog

$GKOS - Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus…

News

GKOS ▲ +8.5% - Glaukos Corporation

CP $175.37▲ +8.5%Oct 7, 2026 · ThinkSabio Blog

$GKOS Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus…

News

GKOS ▼ -0.1% - Glaukos Corporation

CP $161.59▲ -0.1%Oct 7, 2026 · ThinkSabio Blog

$GKOS - Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28…

News

GKOS ▲ +0.0% - Glaukos Corporation

CP $159.86▲ +0.0%Sep 23, 2026 · ThinkSabio Blog

$GKOS - Glaukos Partners with NBA Champion Stephen Curry to Launch “Could it be KC?” Campaign to Raise Awareness of Keratoconus…